GlassScriptPhysician profile
Oral A Waldo
NPI 1124313176
$7,280.86
in general payments reported to CMS, 2019-2025
31 companies · $1,315 in 2025
The $1,315 reported for 2025 was more than what 76% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,980 · 2020: $432 · 2021: $666 · 2022: $639 · 2023: $654 · 2024: $1,594 · 2025: $1,315.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,548 · Consulting Fee: $15.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,548.09 |
| Consulting Fee | $15.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,794.14 | 2019-2025 | Aveir, Amplatzer Amulet, Mitraclip |
| Medtronic, INC. | $580.47 | 2021-2024 | Linq II, Azure Xt Dr Mri Surescan, Reveal Linq |
| Medtronic Vascular, INC. | $491.08 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $342.62 | 2019-2024 | Xarelto |
| Amgen INC. | $328.15 | 2019-2020 | |
| Heartflow, INC. | $290.41 | 2024-2025 | |
| Novo Nordisk INC | $251.65 | 2019-2024 | Ozempic, Wegovy |
| Astellas Pharma US INC | $249.32 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $246.41 | 2022-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $242.65 | 2023-2025 | Camzyos, Eliquis |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $241.05 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $215.41 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $206.69 | 2019-2023 | Farxiga |
| Impulse Dynamics (USA) INC. | $127.44 | 2025 | Optimizer |
| Cvrx, INC. | $108.05 | 2022-2024 | Barostim Neo System |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Irhythm Technologies, INC. | $103.46 | 2024 | Zio Monitor, Zio Xt Patch |
| Elutia, INC. | $102.87 | 2024 | Ecm Patch,Pouch |
| Penumbra, INC. | $53.03 | 2024 | Indigo System |
| Pfizer INC. | $49.77 | 2019-2021 | |
| Alnylam Pharmaceuticals INC. | $40.66 | 2024 | Onpattro |
| Boston Scientific Corporation | $38.68 | 2025 | Watchman Flx |
| Sanofi-Aventis U.S. LLC | $34.92 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $22.81 | 2023 | Opsumit |
| Janssen Scientific Affairs, LLC | $18.84 | 2023 | Xarelto |
| Abbvie INC. | $16.51 | 2019 | |
| Nevro Corp. | $16.09 | 2019 | |
| Baxter Healthcare | $15.00 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Jazz Pharmaceuticals INC. | $14.67 | 2021 | |
| Dexcom, INC. | $13.94 | 2021 | |
| Amarin Pharma, INC. | $12.59 | 2019 | |
| Merck Sharp & Dohme LLC | $11.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Oral Waldo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.